Drugs / Liposomal Cyclosporine A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03657342 | Mar 2019 → Apr 2024 | chronic transplant rejection, transplant-related bronchiolitis obliterans | Zambon SpA | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-04-28 | Zambon SpA | Regulatory A new FDA Fast Track designation for Zambon zambon.com ↗
The FDA’s Fast Track designation for LCsAi represents an important recognition of its potential to address the unmet medical need of patients with BOS, a devastating rare disease with currently no approved treatment, |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-02 | Zambon SpA | Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS) zambon.com ↗ |
| 2020-04-28 | Zambon SpA | A new FDA Fast Track designation for Zambon zambon.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal Cyclosporine A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03657342 ↗ |
| Route | Inhaled | “This formulation is developed for inhalation use” NCT03657342 ↗ |